IRVINE, CA, and HERSTAL, BELGIUM – January 21 2015 – MDxHealth SA (Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that Euronext granted the 2014 Best BEL Small Company Award, for the highest return among its peers, to MDxHealth. The award was presented to Dr. Jan Groen, CEO of MDxHealth, by M. Pieter De Crem, Secretary of State for Foreign Trade, at a ceremony last night at the Palais de la Bourse in Brussels, Belgium.
“We are honoured to receive this prestigious award from Euronext and we would like to thank MDxHealth shareholders, scientific collaborators, the medical community, and reimbursement organizations who have supported and entrusted the Company so far,” stated Dr. Groen. “Several significant milestones were achieved during 2014 and with broader market adoption of our ConfirmMDx test and increasing reimbursement coverage, we are well-positioned for a strong 2015.”
The BEL Small Cap Award is supported by Euronext Brussels, and has established itself as a showcase for the best performing companies within the Belgium small-cap market, providing an opportunity to recognize outstanding achievement.
MDxHealth is a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment. The company’s tests are based on proprietary gene methylation (epigenetics) technology and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. The company’s first commercial product, ConfirmMDx® for Prostate Cancer, has been validated to help distinguish patients who have a true-negative biopsy from those who may have undetected cancer, thereby aiding in the reduction of unnecessary repeat biopsies. For more information visit mdxhealth.com and follow us on Twitter at: twitter.com/mdxhealth.
For more information:
| Dr. Jan Groen, CEO | Mike Sinclair (Media) | |
| MDxHealth | Halsin Partners | |
| US: +1 949 812 6979 | UK: +44 20 7318 2955 | |
| BE: +32 4 364 20 70 | Cell:+44 7968 022075 | |
| info@mdxhealth.com | msinclair@halsin.com |
This press release may contain forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company’s control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.
NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx and PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.
